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12 weeks post-BTM while Group C were sacriﬁced 12 [n = 6], 24 [n = 6]
and 52 [n = 6] weeks post-BTM. At necropsy, both medial compartments
of BTM joints were scored by 2 blinded observers for AC lesions and
osteophytes (OP) using a 0−4 scale. Synovial tissue and a 5mm wide
coronal osteochondral slice were removed from the mid-line of the femur
and tibia and processed for histochemical and histomorphometric analy-
ses using published methods. Intact patellae were used for topographical
biomechanical AC indentation studies.
Results: Gross morphological scores 12 wks post BTM showed a dose-
dependent effect of MPC on AC integrity and OP formation; 100 mil MPC
emerging as the most effective chondroprotective dose relative to HA
alone. Total AC score ratios (HA+MPC)/(HA) showed 100>150>25=10
while OP ratios were 100>25>10>150 mil MPC. Statistically signiﬁcant
(SS) lower scores were observed for total femoral & tibial AC (p = 0.019)
and total AC and OP (p = 0.009) for Group C MPC joints compared HA
alone. Histomorphometric analysis of Group C MPC+HA tibial plateaus
revealed that AC were thicker than the corresponding HA-AC in the middle
(p = 0.057) and outer regions (p = 0.028); for all regions (p = 0.01). The
mean phase lag for the patellae AC of Group C MPC injected joints
was signiﬁcantly lower than the contralateral patella AC (p = 0.002). Mean
modiﬁed Mankin scores for AC sections from Group C MPC+HA joints
were less than corresponding HA sections but were not SS. There was no
evidence of synovial histopathology modulation. The chondroprotective
effects observed for the 100 mil MPC injected joints diminished with time;
the positive effects noted at 12 and 24 weeks BTM being lost by 52 weeks.
Conclusions: This is the ﬁrst report, as far as we are aware, of a
beneﬁcial therapeutic effect of allogenic Stro-3+ MPC on cartilage in-
tegrity in a model of early OA. MPC/MSC are known to release growth
factors and cytokines and also suppress the production of TNF-alpha
by other cells, while up-regulating anti-inﬂammatory cytokines (eg. Il-4,
Il-10). These paracrine activities of MPC could stimulate chondrocyte
biosynthesis of new matrix but also attenuate local production and activity
of catabolic mediators. The ﬁnding in this study that 100 million MPC were
chondroprotective was consistent with such a mechanism of action.
A13 INTRAARTICULAR LUBRICIN SUPPLEMENTATION IS
CHONDROPROTECTIVE AND PREVENTS CARTILAGE
DEGENERATION IN EXPERIMENTAL OSTEOARTHRITIS
C.R. Flannery1, R. Zollner1, C. Corcoran1, A.R.C. Jones1, A. Root1,
M.A. Rivera-Bermudez1, T. Blanchet1, J.P. Gleghorn2, L.J. Bonassar2,
A.M. Bendele3, E.A. Morris1, S.S. Glasson1. 1Wyeth Research,
Cambridge, MA, USA, 2Cornell University, Ithaca, NY, USA, 3Bolder
BioPATH, Boulder, CO, USA
Purpose: Lubricin is a synovial glycoprotein that supplies a friction-
resistant, anti-adhesive coating to the surfaces of articular cartilage,
thereby protecting against arthritis-associated tissue wear and degrada-
tion. We generated and characterized a novel lubricin protein construct,
“LUB:1”, and evaluated its therapeutic efﬁcacy following intraarticular
delivery in a well-characterized rat model of osteoarthritis (OA).
Methods: An optimized lubricin protein construct (designated “LUB:1”),
containing a truncated mucin-like domain, was expressed in stably trans-
fected CHO cells. Puriﬁed LUB:1 was biochemically characterized and
analyzed ex vivo for its ability to bind to and lubricate cartilage surfaces,
and to prevent cellular adhesion. For in vivo studies (IACUC approved),
unilateral OA was induced in the knees of male Lewis rats (n = 20
animals/treatment group) by transection of the medial collateral ligament
and meniscus (‘meniscal tear’-induced OA). At one week post-surgery,
LUB:1 (20mg/40ml), or phosphate-buffered saline (PBS) vehicle (40ml)
was administered by intraarticular injection, with dosing either once per
week or 3 times per week over a subsequent four week period. At the
end of the studies, tissue sections of each knee joint were analyzed
microscopically and assessed for multiple pathological parameters of OA.
Results: LUB:1 maintains functional N-terminal domains which facili-
tate mutimerization, is appropriately substituted with lubricating O-linked
oligosaccharides, and possesses integral C-terminal domains enabling
binding and localization to cartilage surfaces. LUB:1 is an effective carti-
lage boundary lubricant and inhibitor of cellular adhesion. Local delivery
of LUB:1 was therapeutically effective in preventing cartilage degrada-
tion during the progression of OA. Knee joints from rats treated with
LUB:1 developed signiﬁcantly less severe cartilage damage than PBS
(vehicle)-treated animals, and displayed signiﬁcantly reduced cartilage
degeneration scores (general pathology), total joint scores and cartilage
lesion and degeneration width measurements. Strikingly, the width of
severe cartilage lesions, reﬂecting areas of tibial cartilage damage in
which tissue matrix loss extends through 50% or more of the cartilage
depth, was decreased by 83% in response to LUB:1 administered 3 times
per week. Inhibition of loss of viable matrix further indicated beneﬁcial
effects of LUB:1 on overall cartilage tissue preservation (chondrocytes,
proteoglycan and collagen). Subchondral bone scores did not differ be-
tween treatment groups, indicating that joint loading was comparable in all
animals. Evidence of ﬁbroplasia was not observed in response to LUB:1
treatment, thus supporting a favorable tolerability proﬁle for recombinant
lubricin in the treatment of joint diseases.
Conclusions: Intraarticular supplementation of rat knee joints with LUB:1
resulted in signiﬁcant disease-modifying, chondroprotective effects during
the progression of osteoarthritis, by markedly reducing cartilage degener-
ation and structural damage. The use of recombinant lubricin molecules
is thus indicated for novel biotherapeutic approaches in the treatment of
cartilage pathologies associated with osteoarthritis.
A14 CHEMOTAXIS OF HUMAN ARTICULAR CHONDROCYTES
AND MESENCHYMAL STEM CELLS
Y. Mishima, M. Lotz. The Scripps Research Institute, La Jolla, CA, USA
Purpose: Orchestrated movement of cells in a particular direction to a
speciﬁc location is a central process for tissue development, maintenance
and repair. The understanding of cell migration and chemotactic mech-
anisms may lead to the novel therapeutic strategies for tissue repair or
regeneration. The aim of this study was to identify cytokines and growth
factors that are able to induce migration of human articular chondrocytes
and mesenchymal stem cells (MSCs).
Methods: Isolated normal human articular chondrocytes and human
bone marrow-derived MSCs were used. Chemotaxis assays were per-
formed in modiﬁed Boyden chambers using 48-well microchemotaxis
chamber plates with polycarbonate PVP free membranes with 8-mm
pores.
Growth factors were diluted to appropriate concentrations in DMEM/F12
supplemented with 0.1% FBS, and placed in the lower chamber. Approx-
imately 2×104 cells were allowed to attach to the top wells of the insert.
After 24 h incubation, the migrated cells on the lower side of the inserts
were ﬁxed, stained and counted for 4 random ﬁelds per well under light
microscope at 100× magniﬁcation. The results are expressed as total
number of migrated cells.
Results: Progressive chemotactic effects were observed with increasing
FBS concentrations between 0−20%. Among a series of growth factors
and cytokines tested only PDGF induced a signiﬁcant increase in cell
migration. TGFb, VEGF, IGF-1, Il-8, bFGF, BMP-2, BMP-4 and BMP-7
had no signiﬁcant effects on chondrocytes. The PDGF isoforms AB and
BB were more potent than AA. In human articular chondrocytes there
was a signiﬁcant aging related decline in the ability of cells to migrate
in response to serum and PDGF. MSCs signiﬁcantly responded to FBS
and several factors, including FBS, PDGF, VEGF, IGF-1, Il-8, BMP-4 and
BMP-7.
Conclusions: This study demonstrated that directed cell migration is in-
ducible in human articular chondrocytes and MSC and identiﬁed PDGF as
the most potent chemotactic factor. The present results also demonstrate
an aging-related reduction in the migratory response of human articular
chondrocytes. The ability of human articular chondrocytes to migrate in
response to serum and PDGF, supports the potential of augmenting this
cellular response in cartilage repair and tissue engineering.
A15 SUCCESSFUL INTEGRATIVE CARTILAGE REPAIR IN VITRO
CAN BE ACHIEVED BY INHIBITING CHONDROCYTE DEATH
AT THE WOUND EDGE
S.J. Gilbert, S.K. Singhrao, I.K. Khan, V.C. Duance, C. Archer. Cardiff
University, Cardiff, UNITED KINGDOM
Purpose: Experimental wounding of articular cartilage results in necrotic
and apoptotic chondrocyte death at the lesion edge. Viable cells at the
wound edge are critical for producing a repair tissue capable of integrating
with the native cartilage. The aims of this study were to investigate
whether inhibiting the cell death at the wound edge results in enhanced
integrative cartilage repair.
Methods: Full depth, bovine articular cartilage discs (6mm) were har-
vested from the metacarpophalangeal joint of 7-day old calves. Carti-
lage discs were pre-incubated in media containing inhibitors of necrosis
(Necrostatin-1; 30mM) or apoptosis (Z-VAD-FMK, 20mM) prior to cutting
a central 3mm inner core. This core was left in situ to create disc/ring
composites in order to study cartilage-cartilage integration. Cartilage was
cultured for 2-weeks with the above inhibitors and analysed for necrotic
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(LDH release) and apoptotic (TUNEL) cell death, sGAG release (DMMB),
tissue integration (histology, SEM, TEM), and matrix gene expression
(qPCR).
Results: Wounding resulted in a signiﬁcant increase in LDH release
compared to unwounded cartilage (p< 0.001). The pan-caspase inhibitor,
Z-VAD-FMK signiﬁcantly reduced LDH release (p< 0.001) and apoptosis
occurring at the wound edge. Necrostatin-1 also reduced LDH release
(p< 0.01). Both inhibitors reduced the level of sGAG lost into the me-
dia that resulted from wounding the cartilage. Toluidine blue staining,
SEM and TEM of cartilage revealed signiﬁcant integration of the wound
edges in composites treated with Z-VAD-FMK. Necrostatin-1 improved
integration but to a lesser extent. Quantitative PCR analysis revealed
an increase in the expression of type II collagen mRNA in Z-VAD-FMK
treated disc/ring composites.
Conclusions: This study shows that treatment of articular cartilage with
cell death inhibitors prior to and during wound repair increases the
number of viable cells at the wound edge, prevents matrix loss and results
in a signiﬁcant improvement in cartilage-cartilage integration.
A16 DATABASE OF GENE EXPRESSION PATTERNS DURING
CHONDROGENIC DIFFERENTIATION OF HUMAN MSCS
J.F. Welter, L.A. Solchaga, P. Leahy, K.J. Penick, A.I. Caplan,
V.M. Goldberg. Case Western Reserve University, Cleveland, OH, USA
Purpose: Under appropriate culture conditions, mesenchymal stem cells
(MSCs) can rapidly differentiate into chondrocyte-like cells and elaborate
an extracellular matrix that is biochemically similar to that of hyaline
cartilage. This differentiation potential has broad implications for the use
of these cells in cartilage tissue engineering. Immunohistochemical and
biochemical analyses show that, e.g., cartilage ECM molecules become
detectable within the ﬁrst week of the differentiation process. These
phenotypic changes presuppose a radical reprogramming of the gene
expression proﬁles and physiology of MSCs. To support our studies
of chondrogenic MSC differentiation, we have used gene expression
microarrays to create a comprehensive database documenting the se-
quence and extent of these changes.
Methods: Five human MSC (hMSC) preparations, derived from bone
marrow aspirates obtained from the MSC Core Facility at CWRU under
an IRB-approved protocol, were used in these experiments. The cells
were expanded in medium containing serum and FGF-2. After 1 passage,
the cells were moved to aggregate culture at 2.5×105 cells/aggregate in
chondrogenic medium to induce differentiation.
At days 0, 1, 3, 5, and 7, total RNA was extracted from 20 aggre-
gates/timepoint/donor. 5−8mg of spin column-cleanedtotal RNA were
reverse-transcribed. The 3 best quality cDNA preparations were selected
for microarray analysis at the CWRU Gene Expression Array Core Fa-
cility, using Affymetrix HU133-A2 human microarrays (~22,277 full-length
genes and ESTs). Spiked bacterial IVT transcripts served as hybridization
controls.
Raw microarray data were normalized and analyzed using the Affymetrix
Microarray suite and Agilent GeneSpring. Binary comparisons were made
between samples from each time-point. A master list of differentially
expressed transcripts, which were consistently called as either increased
or decreased in all 3 replicates, and had an average absolute fold change
2.0 was deﬁned. These ﬁltered data were then further analyzed using
the Agilent GeneSpring and Ariadne Pathway Studio software packages
for clustering and regulation patterns and for assignment to speciﬁc
cellular pathways.
Results: All 15 arrays passed internal quality control. After ﬁltering data
for credible changes in gene expression, we found a high-value population
of 3,285 differentially expressed genes. Most of these changes occurred
between day 0 and day 1 (1,723), but the number dropped off rapidly
when comparing successive time-points: 315 between day 1 and day 3,
120 between day 3 and day 5, and only 31 between day 5 and day 7.
We conﬁrmed these results by clustering the list of 3,285 genes using
GeneSpring 7.3.1. The gene tree shows that, numerically, most changes
took place within the 1st day, and then began to plateau. Small subsets
of the population spiked or plummeted transiently on day one.
Conclusions: We have created a stringent database of gene expres-
sion changes during early chondrogenic differentiation of human MSCs.
Pattern analysis suggests that the bulk of the gene expression changes,
(both up- and down-regulation) occur within the ﬁrst 24 hours, with most
reﬂecting a permanent change; a much smaller subset showed transient
changes. Overall, this database will be a useful tool for interpreting the
molecular changes associated with chondrogenic differentiation of MSCs.
A17 RADIOGRAPHIC JOINT SPACE NARROWING PREDICTS
MR-BASED CARTILAGE LOSS – DATA FROM THE
OSTEOARTHRITIS INITIATIVE (OAI)
F. Eckstein1, O. Benichou2, W. Wirth3, D.R. Nelson2, S. Maschek3,
M. Hudelmaier1, K. Kwoh4, A. Guermazi5, D. Hunter6, for the OAI
investigators. 1Paracelsus Medical University, Salzburg, AUSTRIA, 2Eli
Lilly & Co, Indianapolis, IN, USA, 3Chondrometrics GmbH, Ainring,
GERMANY, 4Division of Rheumatology and Clinical Immunology,
University of Pittsburgh, Pittsburgh, PA, USA, 5Department of Radiology,
Boston University Medical Center, Boston, MA, USA, 6Division of
Research, New England Baptist Hospital, Boston, MA, USA
Purpose: Radiography can identify knees with structural OA changes,
but it is unclear whether knees with joint space narrowing (JSN) have a
higher likelihood of subsequent cartilage loss in MRI than those without. In
an attempt to examine progression in early and more advanced disease
in the same subjects, it has been suggested that progression may be
assessed in contra-lateral knees, where one knee displays JSN and the
other one does not. We therefore examined whether knees with JSN
at baseline have a higher likelihood of subsequent cartilage loss than
contra-lateral knees with less (or without) JSN.
Methods: The subsample studied was drawn from 2678 cases from the
OA Initiative (OAI public-use datasets1.2.1 Clinical Data set and 1.B.1
Imaging Data set), a multi-center, longitudinal cohort study designed to
identify biomarkers for the development and progression of symptomatic
knee OA. Patients were selected to fulﬁll the following criteria: bilateral
frequent pain (both knees), BMI> 25, medial JSN (OARSI grade 1−3)
in one knee, but no or less medial JSN in the contra-lateral knee, and
no (or less) JSN in the lateral (than in the medial) compartment. The
knees were initially selected based on radiographic status of the site
readings in ﬁxed ﬂexion radiographs and were re-read centrally to conﬁrm
unilateral medial JSN. 80 participants met the eligibility criteria (32 men,
48 women; age = 60.6±9.1 yrs. [mean±SD]; BMI = 31.1±4.0). Of these,
73 were JSN 0 and 7 medial JSN 1 in the less affected knee, whereas
47 were medial JSN 1, 25 JSN 2, and 8 JSN 3 in the more severely
affected knee. Baseline and year 1 follow-up sagittal DESSwe MR images
of both knees (0.7mm slice thickness) were obtained on 3T Siemens
Trio scanners. 7 experienced readers segmented the medial tibial (MT)
and medial femoral condylar (MF) cartilage, with blinding to the order
of acquisition. All segmentations were quality controlled by one reader
(S.M.). The mean cartilage thickness over the entire subchondral bone
area (ThCtAB) was computed using proprietary software. The femoral
condyle was separated into a weight-bearing (cMF) and posterior part
(pMF) at 75% between the trochlear notch and the posterior end of the
femur. The mean change (MC%), SD of change, standardized response
mean (SRM=MC/SD) of ThCtAB were calculated in these regions of the
medial femorotibial compartment.
Results: Whereas knees without JSN showed relatively little progression
in all regions (0 to −1%, SRM−0.33), those with JSN (1−3) tended to
display a higher rate of change (Table 1).
Table 1: Cartilage loss in the medial femorotibial compartment as a function of JSN at baseline
MT cMF pMF
MC% SRM MC% SRM MC% SRM
Knees with less JSN (n = 80)
JSN 0 n=73 −1.0% −0.33 −1.0% −0.16 0.0% 0.0
JSN 1 n=7 −3.9% −0.36 −12% −0.40 −3.9% −0.77
Knees with more JSN (n = 80)
JSN 1 n=43 −1.6% −0.36 −0.3% −0.55 −0.7% −0.15
JSN 2 n=25 −2.9% −0.50 −7.2% −0.70 −3.2% −0.70
JSN 3 n=8 −6.9% −0.62 −12% −1.15 −4.0% −0.49
In the more severely affected knee, the rate of change and SRM increased
with worse grades of JSN (JSN 2 or 3 vs. JSN 1 = p< 0.001 for cMF and
p< 0.05 for pMF). In knees with grade 2 or 3 JSN, the change was higher
in cMF than in MT (p = 0.01) and than in pMF (p = 0.08). The highest
sensitivity to change was observed in the cMF of the JSN 3 knees (n = 8;
SRM=1.15; Table 1).
Conclusions: JSN at baseline predicts subsequent cartilage loss, as
measured by quantitative MRI. The rate and sensitivity to change in-
creased as a function of worsening JSN (1−3). This suggests that MRI-
based measures of cartilage morphometry are particularly responsive at
the later disease stages.
